MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells2017/06/14STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells2017/05/17STEM CELL THERAPEUTIC
Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”2017/04/26STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology2017/01/10STEM CELL THERAPEUTIC
MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada2016/12/01STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells2016/11/30STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US2016/06/30STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug2016/06/08STEM CELL THERAPEUTIC
MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease2016/05/03STEM CELL THERAPEUTIC
